Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Biosciences Sells Specialty Oligo Business to Eurogentec

NEW YORK, May 28 - Epoch Biosciences of Bothell, Wash., today announced the sale of its specialty oligonucleotide business to Liege, Belgium-based Eurogentec.


The sale, for $1.4 million in cash, is expected to close May 30. Epoch will transfer its customer base, manufacturing equipment, and inventory to Eurogentec and the two companies will include North America in an existing supply agreement that allows Eurogentec to sell custom oligonucleotides that include Epoch dyes and non-fluorescent quenchers.


Epoch said that the sale will allow it to focus on its MGB Eclipse probe systems business and will help the company enter the diagnostics market later this year. The company will record a loss of $3 million on the transaction, taking a non-cash write-off for inventory, equipment, and other assets.


Epoch purchased the business, known as Synthetic Genetics, a division of Immune Complex Corp., in November 2000 for $2.6 million to provide manufacturing capacity for the TaqMan MGB probe products marketed by Applied Biosystems.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.